Description: Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer. Target: Autophagy, EGFR. Smiles: Cl.COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1. References: Moyer JD, et al. Induction of apoptosis and cell cycle arrest by...

The hydrochloride salt of a quinazoline derivative with anti-neoplastic properties. Competes with ATP, Erlotinib reversibly binds to EGFR tyroside kinase which blocks the signal transduction events and tumorigenic events associated with EGFR activation.

Soluble in DMSO. Slightly soluble ( 1000-fold more sensitive for EGFR than for c-Src or v-Abl. Target: EGFR , Kinase Group: RTK , Substrate: Tyrosine

Inhibitor of the epidermal growth factor receptor tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer. Erlotinib binds reversibly to the ATP binding site of the receptor. Solubility: Soluble in DMSO at 18mg/ml with warming, very poorly soluble in ethanol, very poorly...

Erlotinib is an EGFR inhibitor (Ki = 2.7 nM). It is greater than 1,000-fold selective for EGFR over Src and Abl at 0.1 µM. Erlotinib induces caspase-3 and -7 activity in NCI H358 non-small cell lung cancer (NSCLC) cells when used at a concentration of 1 µM. Erlotinib (25 mg/kg) reduces EGF-induced EGFR...